Awaiting development: Guidance and quality standards

Showing 51 to 60 of 295

Guidance and quality standards awaiting development
Title	Type
Concizumab for preventing bleeding episodes in haemophilia A or haemophilia B [ID5099]	Technology appraisal guidance
Dabigatran etexilate for the secondary prevention of stroke after an embolic stroke of undetermined source (ID1417)	Technology appraisal guidance
Dabrafenib with trametinib for adjuvant treatment of resected BRAF V600 mutation-positive melanoma in people aged 12 to 17 TS ID 11839	Technology appraisal guidance
Dabrafenib, trametinib or both for treating BRAF V600 mutation-positive unresectable or metastatic melanoma in people aged 12 and over TS ID 11838	Technology appraisal guidance
Daratumumab for treating high-risk smouldering multiple myeloma [ID6214]	Technology appraisal guidance
Daratumumab in combination for untreated multiple myeloma when high-dose chemotherapy and autologous stem cell transplant are suitable ID6249	Technology appraisal guidance
Datopotamab deruxtecan for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer [ID6435]	Technology appraisal guidance
Depemokimab for treating chronic rhinosinusitis with nasal polyps ID 6449	Technology appraisal guidance
Depemokimab for treating severe eosinophilic asthma in people 12 years and over ID6447	Technology appraisal guidance
Dersimelagon for treating erythropoietic protoporphyria and X-linked protoporphyria in people 12 years and over TS ID 10392	Technology appraisal guidance